Very interest potential pathway. A cursory look shows:
- Systemic hypercoagulability is a feature of Covid-19 hence the use of Heparin and in severe cases thrombus formation is seen to be driven by an orchestra of cytokines.
- Heparin in higher dosages lead to significant adverse events and the bioavailability is classified as erratic
- This study found: PPS was as effective as unfractionated heparin, but more effective in inhibiting cell infection than low-molecular-weight heparin
Ann: Quarterly Update and Appendix 4C - quarterly, page-8
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $120.1K | 390.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15615 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 9952 | 5 |
View Market Depth
| Last trade - 13.59pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |